Thromboxane A2 Receptor Biology and Function of a Peculiar Receptor that Remains Resistant for Therapeutic Targeting
Journal of Cardiovascular Pharmacology and Therapeutics, 08/10/2012
Exclusive author commentary
Clinical Article
Ting HJ et al. – It is noteworthy that many US Food and Drug Administration (FDA)–approved drugs have been found to selectively (and nonselectively) block TPR–mediated functional responses, for example platelet aggregation, as described in this review. Therefore, while none of the antagonists, thus far developed for targeting thromboxane A2 receptor (TPR), have made it into clinical use, this peculiar receptor can be antagonized by a large number of drugs used for indications unrelated to thrombosis.
Fadi T. Khasawneh (08/09/2012) comments:
This review provides the knowledge foundation for rational design of novel antagonists for the thromboxane receptor, which is therapeutically relevant in multiple thrombosis-based occlusive disorders.
